Fig 1: The serum level of (A) CT-1 (ng/mL) and (B) IL-17 (ng/L) in psoriasis patients and healthy controls. The black line inside the box represents the median and interquartile range (IQR), and blue and red dots represent individual values in the control and psoriasis groups, respectively. Wilcoxon test: Un-paired Mann–Whitney U test. IL-17, interleukin-17
Fig 2: ROC curves of CT-1 and IL-17 for distinguishing psoriasis patients from healthy controls. IL-17, interleukin-17; CT-1, cardiotrophin-1; AUC, area under the curve; 95% CI, 95% confidence interval; ROC, receiver operating characteristic
Fig 3: Proposed mechanistic link between IL-17–driven psoriatic inflammation and CT-1–mediated cardiometabolic dysfunction (created with Biorender.com). IL-17, interleukin-17; CT-1, cardiotrophin-1; IL-23, interleukin-23; TNF-α, tumor necrosis factor-alpha; NF-κB, nuclear factor kappa B; MAPK, mitogen-activated protein kinase; JAK, Janus kinase; STAT, signal transducer and activator of transcription; LIFR, leukemia inhibitory factor receptor; gp130, glycoprotein 130; GFR, glomerular filtration rate
Supplier Page from Bioassay Technology Laboratory for Human Cardiotrophin 1, CT-1 ELISA Kit